Progyny price target raised to $52 from $48 at Truist

Truist raised the firm’s price target on Progyny to $52 from $48 and keeps a Buy rating on the shares. The company’s 10-Q for Q2 is showing that the in-network provider clinic averages for only Progyny members are higher than the averages of its in network clinics themselves, which demonstrates the value of the company’s care coordination, specialty pharmacy, and member services, the analyst tells investors in a research note.